These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26430904)

  • 1. Review of Bioptic Gleason Scores by Central Pathologist Modifies the Risk Classification in Prostate Cancer.
    Soga N; Yatabe Y; Kageyama T; Ogura Y; Hayashi N
    Urol Int; 2015; 95(4):452-6. PubMed ID: 26430904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
    Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
    Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
    Uesugi T; Saika T; Edamura K; Nose H; Kobuke M; Ebara S; Abarzua F; Katayama N; Yanai H; Nasu Y; Kumon H
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e219-23. PubMed ID: 21640517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
    Burdick MJ; Reddy CA; Ulchaker J; Angermeier K; Altman A; Chehade N; Mahadevan A; Kupelian PA; Klein EA; Ciezki JP
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1439-45. PubMed ID: 18963536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gleason grading challenges in the diagnosis of prostate adenocarcinoma: experience of a single institution.
    Chen SD; Fava JL; Amin A
    Virchows Arch; 2016 Feb; 468(2):213-8. PubMed ID: 26563400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of central pathology review of prostatic biopsies in a contemporary series from a phase III, multicenter, randomized controlled trial (SHIP0804).
    Sasaki H; Kido M; Miki K; Aoki M; Takahashi H; Dokiya T; Yamanaka H; Fukushima M; Egawa S
    Pathol Int; 2015 Apr; 65(4):177-82. PubMed ID: 25707702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
    Huang J; Vicini FA; Williams SG; Ye H; McGrath S; Ghilezan M; Krauss D; Martinez AA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1141-8. PubMed ID: 22099043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Value of Prognostic Grouping of Prostatic Carcinomas for Urologists and Pathologists.
    Helpap B; Ringli D; Breul J; Tonhauser J; Poser I; Seifert HH
    Urol Int; 2015; 95(4):436-44. PubMed ID: 26346556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen.
    Huang CC; Kong MX; Zhou M; Rosenkrantz AB; Taneja SS; Melamed J; Deng FM
    Am J Surg Pathol; 2014 Aug; 38(8):1096-101. PubMed ID: 24832163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
    Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
    Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
    Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revised Gleason grading system is a better predictor of indolent prostate cancer at the time of diagnosis: retrospective clinical-pathological study on matched biopsy and radical prostatectomy specimens.
    Giunchi F; Brunocilla E; Borghesi M; Rizzi S; Ricci MS; Romagnoli D; Martorana G; Schiavina R; Fiorentino M
    Clin Genitourin Cancer; 2014 Oct; 12(5):325-9. PubMed ID: 24583160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer grading: the effect of stratification of needle biopsy Gleason Score 4 + 3 as high or intermediate grade.
    Fanning DM; Kay E; Fan Y; Fitzpatrick JM; Watson RW
    BJU Int; 2010 Mar; 105(5):631-5. PubMed ID: 19732053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can single positive core prostate cancer at biopsy be considered a low-risk disease after radical prostatectomy?
    Ricardo Kupka da S; Dall'Oglio MF; Sant'Ana AC; Pontes J; Srougi M
    Int Braz J Urol; 2013; 39(6):800-7. PubMed ID: 24456772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.